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Patient Characteristics
Characteristics n (%)
Total patients 86(100)
Age, yrs
Less than 50 48(56)
More than 50 38(44)
Diagnosis
AML 34(39)
ALL 10(12)
MDS 16(19)
NHL/HD 8(9)
Others 18(21)
Graft source
Bone marrow 6(7)
Peripheral blood stem cells 80(93)
Conditioning
MA 55(64)
RIC 31(36)
GVHD prophylaxis
CSA/Campath 49(57)
CSA/MMF 33(38)
Others 4(5)338
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Results of children acute lymphoblastic leukemia (ALL)
therapy improved dramatically in the past decades. Patients
with very high risk leukemia may beneﬁt from allogeneic
hematopoieic stem cell transplantation (HSCT) after mye-
loablative conditioning regimen with expected overall
survival of 70%. However such therapy could induce high
toxicity such as acute kidney injury (AKI). In literature, up to
45% of children may experiment acute renal failure during
HSCT. It could increase other toxicities and often leads to
chronic kidney disease.
In this study we retrospectively reviewed medical ﬁles of
patients treated at Robert Debré Hospital in Paris for very
high risk ALL by allogenetic HSCT.
From March 2007 to January 2012, 57 consecutive
patients were included. All patients received a myeloablative
conditioning regimen followed by HSCT from either related
or unrelated 9 and 10/10 HLA compatible donor or 4 to 6/6
cord blood. Patients received TBI in 6 fractions in 3 days from
D-6 to D-3 and then etoposide (60mg/kg) at D-2 in 4 hour-
infusion in central venous line. GvHD prophylaxis was
cyclosporine A (CSA) 1.5mg/kg twice a day in 2-hour infusion
alone for patients transplanted with sibling donor and CSA +
short-course methotrexate and ATG for others.
From the 57 patients, seven patients (14%) developed AKI
at day +1 from etoposid infusion (AKI group), deﬁned by an
increase of creatinine level of more than 2 fold of their own
creatinine basis level and estimated glomerular ﬁltration rate
(EGFR) less than 90 ml/min/1.73m2 the day after etoposide
injection. Another group of 10 patients (17.5%) had
a subclinical AKI with an increase between 1.5 and 2 fold
(sAKI group). EGFR means before graft of the whole cohort
was of 185.7ml/min/1.73m2 [170-200]. At day +1 from eto-
poside infusion, AKI groupe patients eGFR mean was of 55.4
[33-79] (P < .0001) and 95.5 [72-118] (P < .0155) ml/min/
1.73m2respectively. Secondary to acute kidney injury, ﬁve
patients among seven required a delay for stem cell injection.
Two years overall survival at was of 84.4% [76.8-98] and was
not statistically different between control, AKI and sAKI
group. Relapse was similar in all groups (18.6% [42-3.8] for all
patients). Transplanted related mortality was higher in AKI
and sAKI groups versus control group. Indeed 3/17 patients
with persistent complete remission died in those 2 groups
(TRM of 17.6% [0.4-50.6]), while no patient died in control
group (P ¼ .007). Finally, GVH was of 62.8% [49.7;73.4] in
control group, 85.7% [94.1;67.6] in AKI group and 80.6
[92.6;54.6] in sAKI group (p ¼NS).
Acute renal injury is frequent with TBI-VP16 based condi-
tioning regimen for high risk ALL and occurs about 24 hours
afteretoposide injection. It isamajoradverseeffect,may impact
mortality and delay transplantation. Long term consequenceand chronic kidney disease should be evaluated among survi-
vors. Further study are needed to specify these results.339
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Introduction: Invasive fungal infections (IFI) contribute to
morbidity and mortality of hematopoietic cell trans-
plantation (HCT). We evaluated micafungin followed by
posaconazole for primary IFI prophylaxis.
Methods: Consecutive patients who received unrelated HCT
at PMH from July 2009 to Dec 2011 with antifungal
prophylaxis of Micafungin (50 mg IV daily) during hospital-
ization followed by posaconazole (200 mg po tid) for three
months were reviewed.
Results: 86 patients received HCT in above setting. Median
age was 48.3(range 18.6-71.2) years. 71 were 10/10 matches
(allele level) while 15 were 9/10 (allele or antigen mismatch)
(Table 1).
72 (83.7%) developed acute GVHD (aGVHD). Median day
of development of aGVHD was 28.5 (range 7-100) days.
Overall 1 and 2 year survival were 81.2% and 64.1% respec-
tively. Relapse rate was 11.63%.
Median day of start of posaconazole was 22.5 (range
14-64) days. All patients tolerated posaconazole and mica-
fungin well.
3 (3.5%) of patients were diagnosed with IFI in ﬁrst three
months. Median day of diagnosis was 13(range11-81) days.
Diagnosis was based on symptoms with abnormal imaging
and BAL galactomannan positivity in one. Two cases were
treated for symptoms with imaging abnormalities (Table 2).
All patients were switched to voriconazole and improved
which makes it less likely that they were IFI.
Table 2
IFI (EORTC/MSG Criteria)
UPN Symptoms Imaging BAL IFI
27 Yes Ground glass opacity/
consolidation
Galactomannan
+ve
Probable
46 Yes New focal opacity in
previous consolidation
-ve Possible
85 Yes Small b/l pleural effusion
with ground glass opacity
and septal thickening
-ve Possible
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One patient developed oral candidiasis treated with mica-
fungin. One patient had splenic leisons (presumed fungal)
treated with treatment dose posaconazole and improved.
None of these patients had aGVHD at time of IFI diagnosis.
None of these patients died of fungal related causes. 4 out of
5 patients were alive at last follow up. One died of relapse.
Conclusion: Micafungin followed by posaconazole is effec-
tive as primary IFI prophylaxis in unrelated donor HCT.
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Nocardial infection is emerging as an important cause of
morbidity and mortality among hematopoietic stem cell
transplant (HSCT) recipients. Risk factors and outcomes in
this population remain undeﬁned.
We performed a matched case-control study (1:2 ratio).
Cases were deﬁned as recipients of allogeneic HSCT with
a microbiological diagnosis of nocardial infection. Control
subjects were matched for age, timing and transplant type.
Between January 2007 and December 2011, among 440
allogeneic HSCT recipients, 11 (0.03%) were diagnosed with
nocardiosis.
Infection occurred at a median of 510 days (range 139-
1042) after HSCT and was disseminated in 45% of cases.
Diagnoses clustered in the fall (68%). Pulmonary involvement
with nodular inﬁltrates occurred in 91% of cases. Final culture
results were available 55.7 days after diagnostic testing
(range 14-120 days). Nocardia nova was the strain most
commonly isolated (27%). Co-infection with S.aureus, Pseu-
domonas, CMV and Mycobacterium sp. occurred in 73% of all
cases. Trimetroprim-Sulfametoxazole was not protective in 4
out of 11 patients (36%) receiving it for Pneumocystis jirovecii
pneumonia prophylaxis.
In univariate analysis, chronic GVHD (P¼ .011) was asso-
ciated with nocardial infection. Other associated conditions
included bronchiolitis obliterans syndrome (BOS) (P¼ .033),
steroid-induced diabetes mellitus (p¼< .001), and opportu-
nistic infection within the preceding 6 months (p¼ < .001).
Positive CMV serologic status or recent CMV infection were
not signiﬁcant variables. High-dose corticosteroid treatment
within the preceding 6 months (P¼ .005), tacrolimus therapy
(P¼ .002), antifungal prophylaxis (p ¼ <.001), prior autolo-
gous transplant (P¼ .008), and rituximab treatment within12 months (p ¼ < .001) were speciﬁcally associated with
nocardiosis. Patients with Nocardia infection had signiﬁ-
cantly higher mean tacrolimus levels (p ¼ .043), LDH levels
(p ¼ .040), and neutrophil counts (p¼ .002) than controls.
Nocardial infection is an infrequent delayed complication
of allogeneic HSCT primarily affecting recipients with chronic
GVHD. This has biologic correlation, since these patients often
require prolonged immunosuppressive therapies, targeting
both B and T cells, and may have underlying anatomic factors
interferingwithmicrobial clearance, such as bronchiectasis in
BOS. High-dose corticosteroid treatment and its conse-
quences, notably steroid-induced DMII, may increase
susceptibility to this infection. Nocardiosis should be
promptly considered and carefully investigated in susceptible
cGVHD patients, given its adverse impact on prognosis, as
demonstrated by the signiﬁcant reduction in the overall
survival of the infected cohort (72.7% vs 100%, P¼ .013).341
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The Rh D antigen is one of the most immunogenic red
blood cell antigens know. Despite this, it is not considered in
matching schemes for hematopoietic progenitor cell (HPC)
transplants. The frequency of anti-D after Rh mismatched
allogeneic HPC transplants is reportedly low. The objective of
this study was to retrospectively study Rh mismatched HPC
transplants and examine both allogeneic anti-D formation as
well as transplant outcome measures. From January 1999 to
April 2011, 104 consecutive adult Rh mismatched HPC
transplants were performed at our institution and were
available for review. We compared transplants with Rh+
recipients with Rh- donors (R+/D-, n¼60) to those with Rh-
recipients and Rh+ donors (R-/D+, n+44). There was no
difference in underlying diagnoses, graft source, dose of HPC,
degree of HLA matching, conditioning, or type of graft versus
host disease (GVHD) prophylaxis. The median follow-up was
655.5 days (range 14 e 4264 days). Only 2 patients formed
anti-D during the follow-up period, and both were in the R+/
D- group of transplants. One was never exposed to Rh-
positive blood products. The second patient was exposed to
multiple Rh-positive apheresis platelet products prior to
antibody formation. Ten patients formed other red cell allo-
antibodies with no statistical difference between groups. The
most common antibody formedwas anti-E. The overall use of
rbc's and platelets post transplant was similar in both groups,
although the use of Rh-positive rbc's was more common in
the R+/D- group pre-transplant, and the R-/D+ group post-
transplant. A low incidence of chronic GVHD was seen in
both groups (82% of R+/D- transplants had no chronic GVHD,
64% of R-/D+ transplants had no chronic GVHD, P ¼ .045). No
difference in platelet and neutrophil engraftment was
demonstrated.342
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